{"id":44333,"date":"2025-10-24T23:47:09","date_gmt":"2025-10-24T15:47:09","guid":{"rendered":"https:\/\/flcube.com\/?p=44333"},"modified":"2025-10-24T23:47:09","modified_gmt":"2025-10-24T15:47:09","slug":"jiangsu-hengrui-secures-nmpa-approval-to-launch-phase-iii-trial-of-trastuzumab-rezetecan-in-her2%e2%80%91positive-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44333","title":{"rendered":"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer"},"content":{"rendered":"\n<p>China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced today that the National Medical Products Administration (NMPA) has granted approval for a <strong>Phase\u202fIII clinical trial<\/strong> of its antibody\u2011drug conjugate (ADC) <strong>Trastuzumab\u202frezetecan<\/strong>. The study will compare Trastuzumab\u202frezetecan monotherapy with the standard neoadjuvant regimen of <strong>docetaxel\u202f+\u202fcarboplatin\u202f+\u202ftrastuzumab\u202f+\u202fpertuzumab<\/strong> in patients with previously untreated, early or locally advanced HER2\u2011positive breast cancer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-overview\">Product Overview<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong> \u2013 Trastuzumab\u202frezetecan targets HER2\u2011expressing tumor cells, internalizes via receptor\u2011mediated endocytosis, and releases a potent toxin from a protease\u2011cleavable linker inside lysosomes. The released agent induces cell\u2011cycle arrest and apoptosis, offering a highly specific therapeutic profile.<\/li>\n\n\n\n<li><strong>Development<\/strong> \u2013 Independently developed by Hengrui, the ADC has already achieved regulatory clearance in China (May\u202f2025) for the treatment of adult patients with HER2\u2011activating mutant non\u2011small cell lung cancer (NSCLC) who have progressed after at least one systemic therapy.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-trial-design\">Trial Design<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population<\/strong> \u2013 Adults with early or locally advanced HER2\u2011positive breast cancer who have not received prior systemic therapy.<\/li>\n\n\n\n<li><strong>Arms<\/strong><\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Trastuzumab\u202frezetecan monotherapy<\/strong><\/li>\n\n\n\n<li><strong>Standard neoadjuvant therapy<\/strong>: docetaxel\u202f+\u202fcarboplatin\u202f+\u202ftrastuzumab\u202f+\u202fpertuzumab<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Endpoints<\/strong> \u2013 Pathological complete response (pCR) rate, event\u2011free survival, overall survival, and safety profile.<\/li>\n\n\n\n<li><strong>Timeline<\/strong> \u2013 Enrollment to begin Q4\u20112025 with first results expected in 2027.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion<\/strong> \u2013 Positions Hengrui as a key player in HER2\u2011targeted oncology, complementing its existing NSCLC indication.<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong> \u2013 NMPA approval underscores China\u2019s commitment to advancing innovative ADCs and may accelerate global regulatory interest.<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong> \u2013 Successful trial outcomes could unlock significant market potential across China and beyond, targeting the growing demand for next\u2011generation HER2 therapies.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44335,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,62,2586,4228,852],"class_list":["post-44333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National Medical Products Administration (NMPA) has granted approval for a Phase\u202fIII clinical trial of its antibody\u2011drug conjugate (ADC) Trastuzumab\u202frezetecan. The study will compare Trastuzumab\u202frezetecan monotherapy with the standard neoadjuvant regimen of docetaxel\u202f+\u202fcarboplatin\u202f+\u202ftrastuzumab\u202f+\u202fpertuzumab in patients with previously untreated, early or locally advanced HER2\u2011positive breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44333\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National Medical Products Administration (NMPA) has granted approval for a Phase\u202fIII clinical trial of its antibody\u2011drug conjugate (ADC) Trastuzumab\u202frezetecan. The study will compare Trastuzumab\u202frezetecan monotherapy with the standard neoadjuvant regimen of docetaxel\u202f+\u202fcarboplatin\u202f+\u202ftrastuzumab\u202f+\u202fpertuzumab in patients with previously untreated, early or locally advanced HER2\u2011positive breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44333\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T15:47:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2411.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer\",\"datePublished\":\"2025-10-24T15:47:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333\"},\"wordCount\":305,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2411.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44333#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44333\",\"name\":\"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2411.webp\",\"datePublished\":\"2025-10-24T15:47:09+00:00\",\"description\":\"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National Medical Products Administration (NMPA) has granted approval for a Phase\u202fIII clinical trial of its antibody\u2011drug conjugate (ADC) Trastuzumab\u202frezetecan. The study will compare Trastuzumab\u202frezetecan monotherapy with the standard neoadjuvant regimen of docetaxel\u202f+\u202fcarboplatin\u202f+\u202ftrastuzumab\u202f+\u202fpertuzumab in patients with previously untreated, early or locally advanced HER2\u2011positive breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44333\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2411.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2411.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44333#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National Medical Products Administration (NMPA) has granted approval for a Phase\u202fIII clinical trial of its antibody\u2011drug conjugate (ADC) Trastuzumab\u202frezetecan. The study will compare Trastuzumab\u202frezetecan monotherapy with the standard neoadjuvant regimen of docetaxel\u202f+\u202fcarboplatin\u202f+\u202ftrastuzumab\u202f+\u202fpertuzumab in patients with previously untreated, early or locally advanced HER2\u2011positive breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44333","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer","og_description":"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National Medical Products Administration (NMPA) has granted approval for a Phase\u202fIII clinical trial of its antibody\u2011drug conjugate (ADC) Trastuzumab\u202frezetecan. The study will compare Trastuzumab\u202frezetecan monotherapy with the standard neoadjuvant regimen of docetaxel\u202f+\u202fcarboplatin\u202f+\u202ftrastuzumab\u202f+\u202fpertuzumab in patients with previously untreated, early or locally advanced HER2\u2011positive breast cancer.","og_url":"https:\/\/flcube.com\/?p=44333","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T15:47:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2411.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44333#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44333"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer","datePublished":"2025-10-24T15:47:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44333"},"wordCount":305,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44333#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2411.webp","keywords":["ADC \/ XDC","Cancer","Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44333#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44333","url":"https:\/\/flcube.com\/?p=44333","name":"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44333#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44333#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2411.webp","datePublished":"2025-10-24T15:47:09+00:00","description":"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National Medical Products Administration (NMPA) has granted approval for a Phase\u202fIII clinical trial of its antibody\u2011drug conjugate (ADC) Trastuzumab\u202frezetecan. The study will compare Trastuzumab\u202frezetecan monotherapy with the standard neoadjuvant regimen of docetaxel\u202f+\u202fcarboplatin\u202f+\u202ftrastuzumab\u202f+\u202fpertuzumab in patients with previously untreated, early or locally advanced HER2\u2011positive breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44333#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44333"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44333#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2411.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2411.webp","width":1080,"height":608,"caption":"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44333#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui Secures NMPA Approval to Launch Phase\u202fIII Trial of Trastuzumab Rezetecan in HER2\u2011Positive Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2411.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44333"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44333\/revisions"}],"predecessor-version":[{"id":44336,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44333\/revisions\/44336"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44335"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}